• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics

Pear Therapeutics posts mixed bag Q3, cuts 22% of workforce

November 15, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) stock is down today — a day after it reported mixed third-quarter results. The Boston-based prescription digital therapeutic (PDT) developer also announced a large set of layoffs yesterday evening. The new layoffs follow a previous workforce reduction announced over the summer. Shares of PEAR were down more than 3% at $2.44 apiece […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology Tagged With: Pear Therapeutics

Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder

June 14, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]

Filed Under: Big Data, Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Neurological, Patient Monitoring Tagged With: Pear Therapeutics

Pear Therapeutics reports positive real-world data for chronic insomnia treatment

June 8, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Boston-based Pear Therapeutics presented results at the […]

Filed Under: Clinical Trials, Neurological, Technology Tagged With: Pear Therapeutics

Digital therapeutics open up new opportunities in medicine

May 5, 2022 By Sean Whooley

Pear Therapeutics reSET_Check_In (1)

A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]

Filed Under: Business/Financial News, Neurological, Technology Tagged With: Better Therapeutics, dariohealth, Pear Therapeutics, sanofi

FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic

April 13, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate. Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain. Get the full story at our […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Regulatory/Compliance, Technology Tagged With: FDA, Pear Therapeutics

Pear Therapeutics launches program to offer digital therapeutics through telehealth platforms

April 4, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that it launched a program to offer digital therapeutic users access to a telehealth provider. Boston-based Pear’s program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool,” as well as in-person care options. According […]

Filed Under: Big Data, Business/Financial News, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Pear Therapeutics, PursueCare

Pear Therapeutics posts massive Q4 revenue uptick as product sales increase

March 28, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) missed Wall Street’s fourth-quarter revenue projections despite a major year-over-year increase in sales. The Boston-based prescription digital therapeutic (PDT) developer posted profits of $18.8 million, or 13¢ per share, on sales of $1.2 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of nearly $48 million […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Pear Therapeutics

Pear Therapeutics joins Epic App Orchard to enable monitoring of its digital therapeutics

March 24, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that its PearConnect platform is now available in the Epic App Orchard Gallery. By making PearConnect available to healthcare providers through the Epic App Orchard Gallery, the providers who implement the application will be able to access PearConnect within Epic’s electronic health record (EHR) platform, allowing them to monitor patients […]

Filed Under: Big Data, Business/Financial News, Drug-Device Combinations, Featured, Neurological, Patient Monitoring, Technology Tagged With: Pear Therapeutics

Pear Therapeutics to develop digital therapeutic for sleep/wake disorder in Japan

March 21, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that it entered an agreement to develop a Japanese-language digital therapeutic. Boston-based Pear struck a deal with SoftBank, a Japan-based communication and information technology service provider, to develop the digital therapeutic for the treatment of sleep/wake disorders on the Japanese market. Pear Therapeutics markets the Somryst prescription digital therapeutic (PDT) […]

Filed Under: Business/Financial News, Featured, Neurological, Technology Tagged With: Pear Therapeutics

Pear Therapeutics says new data backs its prescription digital therapeutic for insomnia

March 15, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment. Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used […]

Filed Under: Clinical Trials, Featured, Neurological, Technology Tagged With: Pear Therapeutics

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS